9. China Cord Blood ( CO) collects umbilical cord blood stem cells from neonates, and provides laboratory testing, hematopoietic stem cell processing and storage devices.
Analysts polled by Bloomberg expect the company to report earnings of 4 cents per share for the third quarter of fiscal 2011 ended Dec. 31, 2010, in comparison to earnings of 4 cents per share in the year-ago period. Analysts estimate the company to report earnings per share of 18 cents for fiscal 2011 and 23 cents for fiscal 2012, compared to earnings of 10 cents per share reported for fiscal 2009. Of the four analysts covering the stock, 100% recommend buying, in comparison to Examworks Group's ( EXAM) 50% and Healthways' ( HWAY) 23% buy ratings. Analysts expect the stock to gain around 100% over the next 12 months with a consensus target price of $6.8.